Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma

Deanna J. Fall, Holly Stessman, Sagar S. Patel, Zohar Sachs, Brian G. Van Ness, Linda B. Baughn, Michael A. Linden

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Multiple myeloma (MM) is an incurable malignant neoplasm hallmarked by a clonal expansion of plasma cells, the presence of a monoclonal protein in the serum and/or urine (M-spike), lytic bone lesions, and end organ damage. Clinical outcomes for patients with MM have improved greatly over the last decade as a result of the re-purposing of compounds such as thalidomide derivatives, as well as the development of novel chemotherapeutic agents including first and second generation proteasome inhibitors, bortezomib (Bz) and carfilzomib. Unfortunately, despite these improvements, the majority of patients relapse following treatment. While Bz, one of the most commonly used proteasome inhibitors, has been successfully incorporated into clinical practice, some MM patients have de novo resistance to Bz, and the majority of the remainder subsequently develop drug resistance following treatment. A significant gap in clinical care is the lack of a reliable clinical test that would predict which MM patients have or will subsequently develop Bz resistance. Thus, as Bz resistance remains a significant challenge, research efforts are needed to identify novel biomarkers of early Bz resistance, particularly when an early therapeutic intervention can be initiated. Recent advances in MM research indicate that genomic data can be extracted to identify novel biomarkers that can be utilized to select more effective, personalized treatment protocols for individual patients. Computationally integrating large patient databases with data from whole transcriptome profiling and laboratory-based models can potentially revolutionize our understanding of MM disease mechanisms. This systems-wide approach can provide rational therapeutic targets and novel biomarkers of risk and treatment response. In this review, we discuss the use of high-content datasets (predominantly gene expression profiling) to identify novel biomarkers of treatment response and resistance to Bz in MM.

Original languageEnglish (US)
Pages (from-to)720-727
Number of pages8
JournalJournal of Cancer
Volume5
Issue number9
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Computational Biology
Multiple Myeloma
Biomarkers
Proteasome Inhibitors
Gene Expression Profiling
Therapeutics
Thalidomide
Clinical Protocols
Plasma Cells
Bortezomib
Research
Drug Resistance
Blood Proteins
Urine
Databases
Bone and Bones
Recurrence
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma. / Fall, Deanna J.; Stessman, Holly; Patel, Sagar S.; Sachs, Zohar; Van Ness, Brian G.; Baughn, Linda B.; Linden, Michael A.

In: Journal of Cancer, Vol. 5, No. 9, 01.01.2014, p. 720-727.

Research output: Contribution to journalArticle

Fall, Deanna J. ; Stessman, Holly ; Patel, Sagar S. ; Sachs, Zohar ; Van Ness, Brian G. ; Baughn, Linda B. ; Linden, Michael A. / Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma. In: Journal of Cancer. 2014 ; Vol. 5, No. 9. pp. 720-727.
@article{a57f1d51b4d44484b3c84631a80b0689,
title = "Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma",
abstract = "Multiple myeloma (MM) is an incurable malignant neoplasm hallmarked by a clonal expansion of plasma cells, the presence of a monoclonal protein in the serum and/or urine (M-spike), lytic bone lesions, and end organ damage. Clinical outcomes for patients with MM have improved greatly over the last decade as a result of the re-purposing of compounds such as thalidomide derivatives, as well as the development of novel chemotherapeutic agents including first and second generation proteasome inhibitors, bortezomib (Bz) and carfilzomib. Unfortunately, despite these improvements, the majority of patients relapse following treatment. While Bz, one of the most commonly used proteasome inhibitors, has been successfully incorporated into clinical practice, some MM patients have de novo resistance to Bz, and the majority of the remainder subsequently develop drug resistance following treatment. A significant gap in clinical care is the lack of a reliable clinical test that would predict which MM patients have or will subsequently develop Bz resistance. Thus, as Bz resistance remains a significant challenge, research efforts are needed to identify novel biomarkers of early Bz resistance, particularly when an early therapeutic intervention can be initiated. Recent advances in MM research indicate that genomic data can be extracted to identify novel biomarkers that can be utilized to select more effective, personalized treatment protocols for individual patients. Computationally integrating large patient databases with data from whole transcriptome profiling and laboratory-based models can potentially revolutionize our understanding of MM disease mechanisms. This systems-wide approach can provide rational therapeutic targets and novel biomarkers of risk and treatment response. In this review, we discuss the use of high-content datasets (predominantly gene expression profiling) to identify novel biomarkers of treatment response and resistance to Bz in MM.",
author = "Fall, {Deanna J.} and Holly Stessman and Patel, {Sagar S.} and Zohar Sachs and {Van Ness}, {Brian G.} and Baughn, {Linda B.} and Linden, {Michael A.}",
year = "2014",
month = "1",
day = "1",
doi = "10.7150/jca.9864",
language = "English (US)",
volume = "5",
pages = "720--727",
journal = "Journal of Cancer",
issn = "1837-9664",
publisher = "Ivyspring International Publisher",
number = "9",

}

TY - JOUR

T1 - Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma

AU - Fall, Deanna J.

AU - Stessman, Holly

AU - Patel, Sagar S.

AU - Sachs, Zohar

AU - Van Ness, Brian G.

AU - Baughn, Linda B.

AU - Linden, Michael A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Multiple myeloma (MM) is an incurable malignant neoplasm hallmarked by a clonal expansion of plasma cells, the presence of a monoclonal protein in the serum and/or urine (M-spike), lytic bone lesions, and end organ damage. Clinical outcomes for patients with MM have improved greatly over the last decade as a result of the re-purposing of compounds such as thalidomide derivatives, as well as the development of novel chemotherapeutic agents including first and second generation proteasome inhibitors, bortezomib (Bz) and carfilzomib. Unfortunately, despite these improvements, the majority of patients relapse following treatment. While Bz, one of the most commonly used proteasome inhibitors, has been successfully incorporated into clinical practice, some MM patients have de novo resistance to Bz, and the majority of the remainder subsequently develop drug resistance following treatment. A significant gap in clinical care is the lack of a reliable clinical test that would predict which MM patients have or will subsequently develop Bz resistance. Thus, as Bz resistance remains a significant challenge, research efforts are needed to identify novel biomarkers of early Bz resistance, particularly when an early therapeutic intervention can be initiated. Recent advances in MM research indicate that genomic data can be extracted to identify novel biomarkers that can be utilized to select more effective, personalized treatment protocols for individual patients. Computationally integrating large patient databases with data from whole transcriptome profiling and laboratory-based models can potentially revolutionize our understanding of MM disease mechanisms. This systems-wide approach can provide rational therapeutic targets and novel biomarkers of risk and treatment response. In this review, we discuss the use of high-content datasets (predominantly gene expression profiling) to identify novel biomarkers of treatment response and resistance to Bz in MM.

AB - Multiple myeloma (MM) is an incurable malignant neoplasm hallmarked by a clonal expansion of plasma cells, the presence of a monoclonal protein in the serum and/or urine (M-spike), lytic bone lesions, and end organ damage. Clinical outcomes for patients with MM have improved greatly over the last decade as a result of the re-purposing of compounds such as thalidomide derivatives, as well as the development of novel chemotherapeutic agents including first and second generation proteasome inhibitors, bortezomib (Bz) and carfilzomib. Unfortunately, despite these improvements, the majority of patients relapse following treatment. While Bz, one of the most commonly used proteasome inhibitors, has been successfully incorporated into clinical practice, some MM patients have de novo resistance to Bz, and the majority of the remainder subsequently develop drug resistance following treatment. A significant gap in clinical care is the lack of a reliable clinical test that would predict which MM patients have or will subsequently develop Bz resistance. Thus, as Bz resistance remains a significant challenge, research efforts are needed to identify novel biomarkers of early Bz resistance, particularly when an early therapeutic intervention can be initiated. Recent advances in MM research indicate that genomic data can be extracted to identify novel biomarkers that can be utilized to select more effective, personalized treatment protocols for individual patients. Computationally integrating large patient databases with data from whole transcriptome profiling and laboratory-based models can potentially revolutionize our understanding of MM disease mechanisms. This systems-wide approach can provide rational therapeutic targets and novel biomarkers of risk and treatment response. In this review, we discuss the use of high-content datasets (predominantly gene expression profiling) to identify novel biomarkers of treatment response and resistance to Bz in MM.

UR - http://www.scopus.com/inward/record.url?scp=84920919073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920919073&partnerID=8YFLogxK

U2 - 10.7150/jca.9864

DO - 10.7150/jca.9864

M3 - Article

VL - 5

SP - 720

EP - 727

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 9

ER -